Jefferies lowers Scotts Miracle-Gro stock price target to $79

Jefferies cut its price target on Scotts Miracle-Gro (SMG) to $79 from $82 while keeping a Buy rating, implying about 24% upside from the $63.68 share price. The note remains constructive on the company’s outlook, citing Hawthorne operations stabilizing, growth initiatives, and cost reductions, while SMG also posted a Q2 2026 earnings beat with EPS of $4.53 versus $3.86 expected and revenue of $1.46B versus $1.41B expected. The article also highlights a 22-year dividend streak and a 4.04% yield, supporting the fundamentals backdrop.

Analysis

The real signal here is not the revised target itself, but the market’s implied reset from a “deleveraging story” to a “durable cash-return story.” If operating performance is inflecting while balance-sheet risk is falling, the multiple can expand faster than earnings because equity investors tend to re-rate lower-volatility consumer names once the debt overhang starts to fade. That creates a second-order winner profile for the capital structure: equity benefits first from sentiment, then from buyback/dividend capacity if the company proves the improvement is not just a quarter of weather- or inventory-driven noise.

The competitive angle is subtler. A stronger balance sheet and improving execution let SMG spend through the cycle while more levered peers are forced into defensive pricing or underinvestment, which can gradually widen shelf-space and channel-share gaps. But that same dynamic also raises the risk that competitors respond with promotions if they perceive SMG regaining momentum, so the near-term equity setup is more about margin confidence than pure top-line acceleration.

The biggest bear case is that this becomes a “multiple-on-multiple” trade rather than an earnings compounding story: once the market prices in a cleaner balance sheet and mid-single-digit growth, upside gets capped unless absolute growth meaningfully exceeds expectations. The catalyst window is months, not days — the stock likely trades on evidence of sustained margin discipline, free-cash-flow conversion, and whether management can keep leverage moving down without sacrificing the dividend. If growth stalls back toward low single digits, the premium re-rate should compress quickly.

Key Decisions for Investors

• Long SMG versus a consumer/retail basket over 3-6 months: the setup is for valuation expansion if deleveraging and cash flow continue, with downside primarily if growth reverts; use a 10-15% stop if the market starts pricing in a stalled re-rating.
• Buy SMG common into 2-3 post-earnings pullbacks rather than chasing strength: the trade is about confirming that the beat is the start of a multi-quarter inflection, not a one-off; target a 12-20% upside over the next 6-9 months.
• Pair trade: long SMG / short a higher-leverage specialty consumer peer with weaker free-cash-flow conversion, to isolate the balance-sheet re-rating theme; risk is a broad consumer de-rating that hits both legs.
• If options liquidity permits, use a 3-6 month call spread on SMG to express moderate conviction with defined risk; structure for a move toward the prior premium multiple, not a breakout thesis.
• Trim or hedge if management guidance begins to sound promotional rather than evidence-based: the stock likely peaks before the story does, so any slowdown in leverage reduction or margin progress is a signal to take profits.